We are live on ! Find out more
NKTR icon

Nektar Therapeutics
NKTR

227 hedge funds and large institutions have $693M invested in Nektar Therapeutics in 2022 Q2 according to their latest regulatory filings, with 37 funds opening new positions, 79 increasing their positions, 59 reducing their positions, and 45 closing their positions.

New
Increased
Maintained
Reduced
Closed

439% more call options, than puts

Call options by funds: $3.92M | Put options by funds: $727K

34% more repeat investments, than reductions

Existing positions increased: 79 | Existing positions reduced: 59

0.24% more ownership

Funds ownership: 6.29% → 6.53% (+0.24%)

5% less funds holding

Funds holding: 239 → 227 (-12)

18% less first-time investments, than exits

New positions opened: 37 | Existing positions closed: 45

27% less capital invested

Capital invested by funds: $950M → $693M (-$257M)

Holders
227
Holders Change
-12
Holders Change %
-5.02%
% of All Funds
3.82%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
37
Increased
79
Reduced
59
Closed
45
Calls
$3.92M
Puts
$727K
Net Calls
+$3.19M
Net Calls Change
+$9.71M

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$23M
2
First Trust Advisors
First Trust Advisors
Illinois
+$14.5M
3
GPP
Great Point Partners
Connecticut
+$13.2M
4
State Street
State Street
Massachusetts
+$12.3M
5
AllianceBernstein
AllianceBernstein
Tennessee
+$5.64M

Top Sellers

Rank Fund Capital Flow
1
CCM
Camber Capital Management
Massachusetts
-$21.6M
2
BG
Bellevue Group
Switzerland
-$20.1M
3
Millennium Management
Millennium Management
New York
-$10M
4
MC
Maverick Capital
Texas
-$6.62M
5
Balyasny Asset Management
Balyasny Asset Management
Illinois
-$3.6M
Name Holding Trade Value Shares
Change 		Change in
Stake
Carson Wealth (CWM LLC)
201
Carson Wealth (CWM LLC)
Nebraska
$1K -$10.4K -165 -94%
MAM
202
Meeder Asset Management
Ohio
$1K -$1.26K -20 -69%
AWM
203
AllSquare Wealth Management
New York
$1K – – –
First Manhattan
204
First Manhattan
New York
$1K – – –
GWM
205
Geneos Wealth Management
Colorado
$1K – – –
National Bank of Canada
206
National Bank of Canada
Quebec, Canada
$1K – – –
PCG
207
Private Capital Group
Connecticut
$1K +$126 +2 +12%
HI
208
Harbour Investments
Wisconsin
$1K +$631 +10 New
FBC
209
Fairfield, Bush & Co
Connecticut
$1K +$820 +13 New
AAP
210
Arax Advisory Partners
Colorado
$1K +$1.14K +18 New
CA
211
Crewe Advisors
Utah
$1K +$1.51K +24 New
APA
212
American Portfolios Advisors
New York
$874 – – –
BCWM
213
Bartlett & Co Wealth Management
Ohio
$380 – – –
MG
214
MilWealth Group
Wisconsin
$377 – – –
CCM
215
Camber Capital Management
Massachusetts
– -$21.6M -266,667 Closed
Millennium Management
216
Millennium Management
New York
– -$10M -123,642 Closed
Balyasny Asset Management
217
Balyasny Asset Management
Illinois
– -$3.6M -44,588 Closed
Point72 Asset Management
218
Point72 Asset Management
Connecticut
– -$2.39M -29,587 Closed
ECM
219
ExodusPoint Capital Management
New York
– -$2.24M -27,714 Closed
DA
220
Duality Advisers
Florida
– -$1.84M -22,825 Closed
Squarepoint
221
Squarepoint
New York
– -$777K -9,615 Closed
LCM
222
Laurion Capital Management
New York
– -$539K -6,667 Closed
JG
223
Jefferies Group
New York
– -$401K -6,351 Closed
TC
224
TwinBeech Capital
New York
– -$500K -6,183 Closed
SM
225
SG3 Management
Puerto Rico
– -$358K -5,667 Closed
7 8
9
10 11

NKTR Hedge Fund Activity: Q2 2022 in Review

227 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Nektar Therapeutics (NKTR) for Q2 2022, worth a combined $693M — down 27% from $950M a quarter earlier.

Sellers outnumbered buyers: 45 funds closed out of NKTR and 37 opened new positions — a net loss of 8 holders — while 59 trimmed existing stakes and 79 added.

The largest buyer was BlackRock, adding an estimated $23M. The largest seller was Camber Capital Management, exiting entirely with an estimated $21.6M sold.

  • 227 institutional investors held Nektar Therapeutics (NKTR) as of Q2 2022, down from 239 in Q1 2022.
  • Funds reported $693M of Nektar Therapeutics stock for Q2 2022, down 27% quarter-over-quarter.
  • 37 funds opened new Nektar Therapeutics positions in Q2 2022 and 45 closed out, a net change of -8 holders.
  • The largest Nektar Therapeutics buyer in Q2 2022 was BlackRock, an estimated $23M added.
  • The largest Nektar Therapeutics seller in Q2 2022 was Camber Capital Management, an estimated $21.6M sold.

Based on aggregated 13F filings for Q2 2022.